Literature DB >> 26788192

Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans.

Akiko Ezuka1, Eiji Sakai2, Kenichi Kawana1, Hajime Nagase1, Yukio Kakuta3, Shiori Uchiyama2, Hidenori Ohkubo2, Takuma Higurashi2, Takashi Nonaka2, Hiroki Endo2, Hirokazu Takahashi4, Atsushi Nakajima2.   

Abstract

Aberrant crypt foci (ACF) are regarded as potential biomarkers for colorectal cancer (CRC), and have been used as such in recent early-phase chemoprevention trials. However, the associations between the presence of ACF and other factors associated with the development of CRC, such as lifestyle factors, medication use and comorbid medical conditions, remain unknown. Thus, the present retrospective, large, cross-sectional study was conducted to evaluate the potential usefulness of ACF as a surrogate biomarker of CRC. Total colonoscopy was performed and the number of rectal ACF was counted in a total of 902 subjects. A retrospective review of the medical records of the study subjects was performed, and the factors associated with the increased prevalence of ACF was investigated using univariate and multivariate logistic regression analyses. The analysis results identified older age [odds ratio (OR), 9.24; 95% confidence interval (CI), 4.80-17.8; P<0.01], smoking habit (OR, 1.78; 95% CI, 1.20-2.63; P<0.01) and use of insulin (OR, 9.97; 95% CI, 1.28-77.5; P=0.03) as significant independent risk factors associated with the increased prevalence of ACF, regardless of the presence/absence of colon tumors. In addition, it was revealed that the prevalence and number of ACF, and the Ki-67 labeling indices of the colonic epithelial cells were significantly higher in diabetic patients receiving insulin therapy than in those not receiving insulin therapy (P<0.01, P=0.03 and P=0.01, respectively). In conclusion, the potential usefulness of ACF as a surrogate biomarker of CRC was confirmed, although useful data could not be obtained on candidate chemopreventive agents. These results indicated that insulin can enhance colonic epithelial proliferative activity and induce the formation of ACF, thereby possibly triggering CRC development.

Entities:  

Keywords:  Ki-67; aberrant crypt foci; colorectal cancer; colorectal carcinogenesis; insulin

Year:  2015        PMID: 26788192      PMCID: PMC4665697          DOI: 10.3892/ol.2015.3763

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Aberrant crypt foci in human colons: distribution and histomorphologic characteristics.

Authors:  B Shpitz; Y Bomstein; Y Mekori; R Cohen; Z Kaufman; D Neufeld; M Galkin; J Bernheim
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

2.  Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.

Authors:  Hidenori Ohkubo; Hirokazu Takahashi; Eiji Yamada; Eiji Sakai; Takuma Higurashi; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Masataka Taguri; Atsushi Nakajima
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

3.  Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Authors:  Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Michiko Sugiyama; Eiji Sakai; Takashi Uchiyama; Kaori Suzuki; Hiroshi Iida; Yasunari Sakamoto; Kyoko Yoneda; Tomoko Koide; Chikako Tokoro; Yasunobu Abe; Masahiko Inamori; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-01

4.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis.

Authors:  Susanna C Larsson; Nicola Orsini; Alicja Wolk
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

Review 5.  Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis.

Authors:  David P Hurlstone; Simon S Cross
Journal:  J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 4.029

6.  Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Authors:  Tetsuji Takayama; Hiroyuki Nagashima; Masahiro Maeda; Shuichi Nojiri; Michiaki Hirayama; Yoichiro Nakano; Yasuo Takahashi; Yasushi Sato; Hitoshi Sekikawa; Mitsuru Mori; Tomoko Sonoda; Tetsuo Kimura; Junji Kato; Yoshiro Niitsu
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

7.  Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Authors:  Nancy L Cho; Mark Redston; Ann G Zauber; Adelaide M Carothers; Jason Hornick; Andrew Wilton; Stephen Sontag; Norman Nishioka; Francis M Giardiello; John R Saltzman; Chris Gostout; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2008-04-14

Review 8.  Genomic and epigenetic instability in colorectal cancer pathogenesis.

Authors:  William M Grady; John M Carethers
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

Review 9.  Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events.

Authors:  Alireza Ansary Moghaddam; Mark Woodward; Rachel Huxley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

10.  Aberrant crypts: putative preneoplastic foci in human colonic mucosa.

Authors:  T P Pretlow; B J Barrow; W S Ashton; M A O'Riordan; T G Pretlow; J A Jurcisek; T A Stellato
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  5 in total

1.  The distribution of human rectal aberrant crypt foci and criteria for defining the counting area.

Authors:  Tetsuro Fujii; Eiji Sakai; Hirokazu Takahashi; Eiji Yamada; Hidenori Ohkubo; Takuma Higurashi; Atsushi Nakajima
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

2.  Lung cancer patients with synchronous colon cancer.

Authors:  Koich Kurishima; Kunihiko Miyazaki; Hiroko Watanabe; Toshihiro Shiozawa; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2017-10-27

3.  High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study.

Authors:  Alexandra Vulcan; Jonas Manjer; Bodil Ohlsson
Journal:  BMC Cancer       Date:  2017-12-12       Impact factor: 4.430

4.  Epigallocatechin gallate inhibits dimethylhydrazine-induced colorectal cancer in rats.

Authors:  Yu Wang; Hei-Ying Jin; Ming-Zhi Fang; Xiao-Feng Wang; Hao Chen; Shu-Liang Huang; De-Song Kong; Min Li; Xiu Zhang; Yu Sun; Shui-Ming Wang
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

5.  Synbiotic Combination of Djulis (Chenopodium formosanum) and Lactobacillus acidophilus Inhibits Colon Carcinogenesis in Rats.

Authors:  Chih-Wei Lee; Hong-Jhang Chen; Yu-Hua Chien; Shih-Min Hsia; Jiann-Hwa Chen; Chun-Kuang Shih
Journal:  Nutrients       Date:  2019-12-30       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.